Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects
Jing-shun Zhang,
Yuan-dong Sun,
Yuan-min Li,
Jian-jun Han
Affiliations
Jing-shun Zhang
Department of Thoracic Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, Shandong, China
Yuan-dong Sun
Department of Interventional Radiology, Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, Shandong, China; Corresponding author. Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Ji'nan, Shandong Province, CN, 250117, China.
Yuan-min Li
Key Laboratory of Transplant Engineering and Immunology, NHC, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, China
Jian-jun Han
Department of Interventional Radiology, Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, Shandong, China; Corresponding author. Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Ji'nan, Shandong Province, CN, 250117, China.
This review examines combining tumor ablation therapy with immunotherapy for respiratory and digestive system tumors, particularly NSCLC and liver cancer. Despite advancements in traditional methods, they face limitations in advanced-stage tumors. Ablation techniques like RFA, MWA, and cryoablation offer minimally invasive options, while immune checkpoint inhibitors enhance the immune system's tumor-fighting ability. This review highlights their synergistic effects, clinical outcomes, and future research directions, including optimizing protocols, exploring new combinations, uncovering molecular mechanisms, advancing precision medicine, and improving accessibility. Combined therapy is expected to improve efficacy and patient outcomes significantly.
